BICALUTAMIDE ANALOGS OR (S)-BICALUTAMIDE AS EXOCYTOSIS ACTIVATING COMPOUNDS FOR USE IN THE TREATMENT OF A LYSOSOMAL STORAGE DISORDER OR GLYCOGENOSIS
申请人:BCN Peptides, S.A.
公开号:EP3086784B9
公开(公告)日:2019-10-16
Bicalutamide Analogs Or (S)-Bicalutamide As Exocytosis Activating Compounds For Use In The Treatment Of A Lysosomal Storage Disorder Or Glycogenosis
申请人:BCN PEPTIDES, S.A.
公开号:US20160317489A1
公开(公告)日:2016-11-03
SUMMARY The invention provides a therapy for lysosomal storage diseases and glycogenosis by treatment with compounds that promote exocytosis, preferably lysosomal exocytosis. The treatment of cells from patients affected by different lysosomal storage disorders with exocytosis activating compounds leads to a decrease in the accumulation of toxic substrate in the lysosomes, thus allowing the treatment, prevention and relief of the symptoms of many lysosomal storage disorders.
[EN] BICALUTAMIDE ANALOGS OR (S)-BI CALUTAM IDE AS EXOCYTOSIS ACTIVATING COMPOUNDS FOR USE IN THE TREATMENT OF A LYSOSOMAL STORAGE DISORDER OR GLYCOGENOSIS<br/>[FR] ANALOGUES DU BICALUTAMIDE OU (S)-BICALUTAMIDE EN TANT QUE COMPOSÉS ACTIVANT L'EXOCYTOSE POUR LEUR UTILISATION DANS LE TRAITEMENT D'UN TROUBLE DE SURCHARGE LYSOSOMALE OU DE LA GLYCOGENÈSE
申请人:BCN PEPTIDES SA
公开号:WO2015097088A1
公开(公告)日:2015-07-02
SUMMARY The invention provides a therapy for lysosomal storage diseases and glycogenosis by treatment with compounds thatpromote exocytosis, preferably lysosomal exocytosis. The treatment of cells frompatients affected by different lysosomal storage disorders with exocytosis activating compounds leads to a decreaseinthe accumulation of toxic substrate in the lysosomes, thus allowingthe treatment,prevention and relief of the symptoms of many lysosomal storage disorders.
Chiral Nonsteroidal Affinity Ligands for the Androgen Receptor. 1. Bicalutamide Analogues Bearing Electrophilic Groups in the B Aromatic Ring
作者:Leonid Kirkovsky、Arnab Mukherjee、Donghua Yin、James T. Dalton、Duane D. Miller
DOI:10.1021/jm990027x
日期:2000.2.1
parent molecule were synthesized. These compounds were designed as affinity ligands for the androgen receptor (AR). We prepared the (R)- and (S)-optical isomers of these compounds as pure enantiomers. The AR binding affinities of these compounds were measured in a competitive binding assay with the radiolabeled high-affinity AR ligand, [(3)H]mibolerone. In accordance with our previous results for the enantiomers